Pregled bibliografske jedinice broj: 31224
Unusual marker expression in acute leukaemia is associated with low remission rate
Unusual marker expression in acute leukaemia is associated with low remission rate // V. seminar New Trends in the Treatment of Acute Leukemia / Mrsić, Mirando ; Labar, Boris (ur.).
Zagreb: University Hospital Rebro Zagreb and European School of Oncology, 1998. str. 26-26 (poster, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 31224 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Unusual marker expression in acute leukaemia is associated with low remission rate
Autori
Mrsić, Mirando ; Batinić, Drago ; Mrsić, Sanja ; Boban, Dubravka ; Nemet, Damir ; Užarević, Branka ; Bogdanić, Vinko ; Aurer, Igor ; Radman, Ivo ; Marković-Glamočak, Mirjana ; Sučić, Mirna ; Sertić, Dubravka ; Pisk, Mirta ; Marušić, Matko ; Labar, Boris
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
V. seminar New Trends in the Treatment of Acute Leukemia
/ Mrsić, Mirando ; Labar, Boris - Zagreb : University Hospital Rebro Zagreb and European School of Oncology, 1998, 26-26
Skup
V. seminar New Trends in the Treatment of Acute Leukemia
Mjesto i datum
Dubrovnik, Hrvatska, 06.09.1998. - 09.09.1998
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
mixed leukemia; immunophenotype; prognosis
Sažetak
From 1988. to 1998. a total of 40 patients with acute leukaemia (AL) presented with unusual blast immunophenotype. There were 12 females (30%) and 28 males (70%), aged 20-60 (median 41). The FAB types were ALL (10), ALL-L1 (4), undifferentiated AL (AUL, 18) and AML-M1 (8). The basic panel of reagents run on all patients included CD2, CD5, CD10,CD19, CD13,CD33, Cdw65, HLA-DR and CD34, followed by various second-line linegae-associated reagents. Cytogenetic abnormalities were found in 16 of 40 patients with unusual blast-immunophenotype. Match-pair analysis was conducted according to age, sex, FAB, cytogenetic abnormalities and number of WBC at diagnosis. Two control groups were established: AML (n=51) and ALL (n=26). Remission rate for patients with unusual blast marker expression was 48%, which was in contrast to AML (74%) and ALL (68%) (p<0.02). Median remission duration for AL with unusual blast immunophenotype was 6 months (3-15), for AML 18 months (3-42) and for ALL 16 months (3-38) (p<0.02). Probability of relapse was 75% for unusual AL, 42% for AML and 52% for ALL (p<0.03, long rank analysis). However, the probability of leukemia free survival was not different among three studied groups of patients. In conclusion, patients who presented with AL with unusual blast-immunophenotype had significantly lower remission rate and higher relapse rate.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Mirando Mrsić
(autor)
Matko Marušić
(autor)
Dubravka Sertić
(autor)
Dubravka Boban
(autor)
Drago Batinić
(autor)
Boris Labar
(autor)
Mirjana Marković-Glamočak
(autor)
Mirna Sučić
(autor)
Branka Užarević
(autor)
Igor Aurer
(autor)
Vinko Bogdanić
(autor)
Damir Nemet
(autor)
Ivo Radman-Livaja
(autor)